Clinical Trial

Boost GVAX Pancreas Vaccine With or Without CY in Patients With Pancreas Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and feasibility of long term boost vaccination of a lethally irradiated, allogenic pancreatic tumor cell vaccine transfected with the granulocyte macrophage colony-stimulating factor (GM-CSF) gene (GVAX Pancreas Vaccine) alone or given in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the pancreas.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2010-03-16; most recent amendment 2025-08-06.
Status change: Recruiting → Active, Not Recruiting 2023-03-06
Status change: Active, Not Recruiting → Recruiting 2012-10-02
Status change: Recruiting → Active, Not Recruiting 2011-07-19
Status change: Not Yet Recruiting → Recruiting 2010-08-05
Trial Details
NCT Number NCT01088789
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: The Skip Viragh Foundation
Conditions Pancreatic Cancer
Enrollment 71 participants
Start Date 2010-04-20
Primary Completion 2024-07-17 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-26